Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
Real-time Estimate Cboe Europe  -  09:23 2022-10-07 am EDT
221.85 SEK   +0.11%
09/30Sobi - New number of shares and votes in Swedish Orphan Biovitrum AB
AQ
09/30New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
AQ
09/16ADC Therapeutics, Sobi Say CHMP Opinion Positive for Zynlonta for Relapsed or Refractory Diffuse Large B-cell Lymphoma
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
10/03/2022 10/04/2022 10/05/2022 10/06/2022 10/07/2022 Date
216.6(c) 222.2(c) 221.5(c) 221.6(c) 221.6 Last
391 887 354 497 282 751 260 690 57 101 Volume
+0.46% +2.59% -0.32% +0.05% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2022 18 137 M 1 636 M 1 636 M
Net income 2022 2 344 M 211 M 211 M
Net Debt 2022 6 940 M 626 M 626 M
P/E ratio 2022 28,0x
Yield 2022 -
Sales 2023 19 403 M 1 750 M 1 750 M
Net income 2023 3 290 M 297 M 297 M
Net Debt 2023 3 349 M 302 M 302 M
P/E ratio 2023 20,0x
Yield 2023 -
Capitalization 65 592 M 5 917 M 5 917 M
EV / Sales 2022 4,00x
EV / Sales 2023 3,55x
Nbr of Employees 1 554
Free-Float 57,8%
More Financials
Company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the... 
Read more
Sector
Pharmaceuticals
Calendar
10/27 | 02:00amEarnings Release
More about the company
Ratings of Swedish Orphan Biovitrum AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
09/30Sobi - New number of shares and votes in Swedish Orphan Biovitrum AB
AQ
09/30New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
AQ
09/16ADC Therapeutics, Sobi Say CHMP Opinion Positive for Zynlonta for Relapsed or Refractor..
MT
09/16Swedish Orphan Biovitrum, ADC Therapeutics Win Recommendation For Lymphoma Medication
MT
09/16ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive..
CI
09/16ADC Therapeutics, Swedish Orphan Biovitrum's Co-Developed Drug Recommended for EU Autho..
DJ
09/16EU regulator backs wider use of AstraZeneca COVID therapy
RE
08/30FDA grants priority review to efanesoctocog alfa for people with haemophilia A
AQ
08/30Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Bio..
CI
07/21DRI Healthcare Trust Acquires Royalty Interest in Global Sales of Pegcetacoplan For US$..
MT
07/19Biovitrum AB - The Board of Directors exercises authorisation for repurchase of shares ..
AQ
07/19Transcript : Swedish Orphan Biovitrum AB, Q2 2022 Earnings Call, Jul 19, 2022
CI
07/19Sobi Sees Revenue Growth at Higher End of Guidance on Expanded Pipeline, Market Presenc..
MT
07/19Sobi publishes Q2 2022 report
AQ
07/19Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2022
CI
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
09/28Avis d'analystes du jour : Pernod Ricard, Renault, Ipsen, Virba..
09/16ADC Therapeutics et Sobi déclarent que l'avis du CHMP est positif pour le Zynlonta dans..
09/16L'orphelin suédois Biovitrum et ADC Therapeutics obtiennent une recommandation pour un ..
09/16ADC Therapeutics et Sobi annoncent que ZYNLONTA® (loncastuximab tesirine) a reçu un avi..
09/16Le régulateur européen soutient une utilisation plus large du traitement COVID d'AstraZ..
More news
ETFs positioned on SWEDISH ORPHAN BIOVITRUM AB (PUBL)ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
First Trust IPOX Europe Equity Opportunitie...3.41%1.44%-NC
First Trust IPOX® Europe Equity Opportuniti...3.4%3.76%Europe
First Trust International IPO ETF - USD1.28%2.49%World
XACT Sverige - SEK1.11%1.76%Sweden
IShares STOXX Europe Small 200 (DE) - EUR0.76%4.29%Europe
More ETFs positioned on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 221,60 SEK
Average target price 255,00 SEK
Spread / Average Target 15,1%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Håkan Björklund Chairman
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Christine Wesström Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)19.72%5 917
CSL LIMITED-0.18%90 028
SAMSUNG BIOLOGICS CO.,LTD.-10.08%41 052
BIOGEN INC.9.31%38 057
WUXI BIOLOGICS (CAYMAN) INC.-46.25%26 995
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.63%19 439